Yahoo
NasdaqGS - Nasdaq Real Time Price USD

10x Genomics, Inc. (TXG)

70.11 -11.44 (-14.03%)
At close: October 30 at 4:00:00 PM EDT
69.80 -0.31 (-0.44%)
After hours: October 30 at 7:23:16 PM EDT
Trade TXG on Coinbase
Chart Range Bar
Loading chart for TXG
  • Previous Close 81.55
  • Open 73.65
  • Bid 53.74 x 200
  • Ask 87.32 x 200
  • Day's Range 67.42 - 75.77
  • 52 Week Range 12.44 - 102.81
  • Volume 5,215,260
  • Avg. Volume 3,398,815
  • Market Cap (intraday) 9.135B
  • Beta (5Y Monthly) 1.99
  • PE Ratio (TTM) --
  • EPS (TTM) -0.59
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 77.50
  • Zacks Rating Bullish

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

www.10xgenomics.com

1,178

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TXG
329.86%
S&P 500 (^GSPC)
10.73%

1-Year Return

TXG
463.59%
S&P 500 (^GSPC)
11.11%

3-Year Return

TXG
96.11%
S&P 500 (^GSPC)
81.91%

5-Year Return

TXG
56.53%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 151.04M
Earnings -17.93M
Profit Margin -11.87%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
-18.0%
-16.0%
-14.0%
-12.0%
-10.0%

Analyst Insights

View More

Analyst Price Targets

50.00 Low
77.50 Average
70.11 Current
110.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 47 -> 70

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.18%

  • Return on Assets (ttm)

    -5.05%

  • Return on Equity (ttm)

    -9.40%

  • Revenue (ttm)

    616.91M

  • Net Income Avi to Common (ttm)

    -75.12M

  • Diluted EPS (ttm)

    -0.59

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    552.03M

  • Total Debt/Equity (mrq)

    9.54%

  • Levered Free Cash Flow (ttm)

    179.66M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: